Form 4: Sarepta Therapeutics Executive Dallan Murray Reports Stock Sale for Tax Obligations
SEC Form 4 Filing
Chief Customer Officer Dallan Murray of Sarepta Therapeutics reports selling shares to cover tax obligations related to vesting restricted stock units.
Summary
- Dallan Murray, Chief Customer Officer of Sarepta Therapeutics, filed a Form 4 on March 4, 2025, reporting a transaction on March 3, 2025.
- The transaction involved the sale of 711 shares of common stock at a price of $103.77 per share to satisfy tax withholding obligations related to the vesting of restricted stock units granted on March 1, 2024.
- Following the transaction, Murray beneficially owns 21,506 shares of Sarepta Therapeutics common stock, which includes 194 shares purchased under the company's Employee Stock Purchase Plan on February 28, 2025.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a routine stock transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a sale of shares to cover tax obligations, which is a common practice.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| March 1, 2024 | Date of grant for restricted stock units that triggered the tax obligation. |
| February 28, 2025 | Date of purchase of 194 shares under the Employee Stock Purchase Plan. |
| March 3, 2025 | Date of the stock sale transaction. |
| March 4, 2025 | Date of filing the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.